samedan logo
 
 
spacer
home > ict > summer 2018 > perfecting practices
PUBLICATIONS
International Clinical Trials

Perfecting Practices

Over the past decade, the focus on technology as a driver of performance improvement in clinical trials has been intense (1- 2). This is particularly true for study start-up, a widely recognised bottleneck encompassing the activities associated with site identification, feasibility assessment, selection, and activation required before the first patient can be enrolled in a study.

Practices intended to streamline study start-up timelines include the use of technology investments to expedite the collection of clinical data and to help sponsors/CROs better monitor clinical trial performance, but, despite many attempts at improvement within organisations, gains in end-to-end cycle time have not been made (3).

A comprehensive survey conducted by the Tufts Center for the Study of Drug Development determined that a mere 8% of sponsors and 14% of CROs are extremely satisfied with their study start-up processes (4). By comparison, approximately 40% are either somewhat or completely unsatisfied with those methods. Respondents reporting that they are extremely satisfied have cycle times 57.5% shorter than those claiming to be completely unsatisfied.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Craig Morgan is a technology and life sciences management professional with more than 15 years of experience in the application of informatics and bioinformatics to drug discovery. He currently heads up the marketing and brand development functions at goBalto, working with sponsors, CROs, and sites to reduce cycle times and improve collaboration and oversight in clinical trials.
spacer
Craig Morgan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Publishes New Research On the Mechanisms Underlying the C-DILI Assay

BioIVT, a leading provider of research models and services for drug development, today announced its research into the mechanisms involved in cholestatic drug-induced liver injury (DILI) has been published in Applied In Vitro Toxicology.1
More info >>

White Papers
 
Industry Events

SMiís 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement